Free shipping on all orders over $ 500

Rigosertib sodium

Cat. No. M2211

All AbMole products are for research use only, cannot be used for human consumption.

Rigosertib sodium Structure
Synonym:

ON-01910 sodium; CAS# 592542-60-4

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 66  USD66 In stock
10mg USD 110  USD110 In stock
25mg USD 200  USD200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Rigosertib sodium (ON-01910 sodium salt) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM. Rigosertib (ON-01910) inhibited polo-like kinase1 (Plk1), induced apoptosis in CLL B cells without significant toxicity against T cells or normal B cells. Rigosertib also inhibits several multidrug resistant tumor cell lines, including MES-SA, MES-SA/DX5a, CEM, and CEM/C2a, with IC50 of 50-100 nM. Rigosertib also abrogates the pro-survival effect of follicular dendritic cells on CLL cells and reduces SDF-1-induced migration of leukemic cells. Rigosertib (200 mg/kg) shows inhibition on tumor growth in a mouse xengraft model of BT20 cells in vivo.

Chemical Information
Molecular Weight 473.47
Formula C21H24NNaO8S
CAS Number 1225497-78-8
Solubility (25°C) DMSO 90 mg/mL
Water 50 mg/mL
Storage 2-8°C, dry, sealed
References

[1] Chapman CM, et al. Clin Cancer Res. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

[2] Ma WW, et al. Clin Cancer Res. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.

Related PLK Products
(1E)-CFI-400437 dihydrochloride 

(1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM).

3MB-PP1

3MB-PP1 is a bulky purine analog and inhibitor of Polo-like kinase 1 (Plk1) that blocks mitotic progression and cytokinesis by targeting Plk1 in cells expressing the analog-sensitive Plk1 allele. 3MB-PP1 also specifically inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). 3MB-PP1 inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). In addition, 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits the Leu93 mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used in the mycelium of Candida albicans. 3MB-PP1 can be used in studies related to mycelium formation and cell division in Candida albicans.

CYC-800

CYC-800 is a PLK1 inhibitor that can be used in tumor-related studies.

SOL-686

SOL-686 is a PLK1 inhibitor that can be used in glioma-related studies.

BAL0891

BAL0891 is a potential first-in-class PLK1/TTK inhibitor with antiproliferative activity for studies related to solid tumors.

  Catalog
Abmole Inhibitor Catalog




Keywords: Rigosertib sodium, ON-01910 sodium; CAS# 592542-60-4 supplier, PLK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.